Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Remimazolam [0.03%]
瑞美扎 Mendle在我国临床药理学中的药物相互作用
Derek E Murrell,Sam Harirforoosh
Derek E Murrell
Remimazolam, an ultrashort-acting benzodiazepine, has emerged as a promising sedative agent for procedural sedation and general anesthesia. It combines the favorable properties of traditional benzodiazepines with a rapid onset and offset of...
Development and Validation of an HPLC-MS/MS Method for Quantitative Bioanalysis of Lidocaine and its Metabolites in Human Plasma: Application in a Population Pharmacokinetic Study [0.03%]
定量测定人血浆中利多卡因及其代谢物的HPLC-MS/MS法的建立及验证：在人群药代动力学研究中的应用
Keng Wah Foong,Didi Erwandi Mohamad Haron,Sook Hui Chaw et al.
Keng Wah Foong et al.
Background and objective: Lidocaine is increasingly used perioperatively as a systemic analgesic. Quantification of lidocaine and its active metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX), is essent...
Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers [0.03%]
两种盐酸二甲双胍片空腹及餐后人体生物等效性与药代动力学评价试验
Yuxing Huang,Qiuhan Cai,Meifang Li et al.
Yuxing Huang et al.
Background and objectives: With diabetes prevalence rising and original formulations unable to meet demand, establishing generic equivalence is crucial for treatment accessibility. This study evaluated the bioequivalence ...
PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug Exposure [0.03%]
阿巴西帕酶在AIEOP-BFM ALL 2009试验中急性淋巴细胞白血病儿童患者中的群体药代动力学和药物暴露特征分析
Gudrun Würthwein,Christian Siebel,Claudia Lanvers-Kaminsky et al.
Gudrun Würthwein et al.
Background and objectives: Focusing on pharmacokinetic-derived individual dose-intensity parameter values (DIPs), we modeled the pharmacokinetics of polyethylene glycol-conjugated asparaginase (PEG-ASNase) in all treatmen...
Simulated Dosing Regimens of Subcutaneous Infliximab in Adults and Children with Inflammatory Bowel Disease: Exploring Switch and Initiation Strategies [0.03%]
模拟成人和儿童炎症性肠病患者使用英夫利西单抗皮下注射的给药方案：转换及起始策略探索研究
Rianne A Weersink,Ron J Keizer,Luc J J Derijks
Rianne A Weersink
Introduction: An increasing number of patients in clinical practice are transitioning from intravenous (IV) to subcutaneous (SC) dosing of infliximab. In this simulation study, we evaluated hypothetical dosing scenarios b...
Evaluation of the Effect of Ticagrelor Dose Interruption and Treatment Resumption with or without Bolus Doses Through Population PK/PD Simulation [0.03%]
基于人群PK/PD模拟评估替格瑞洛停药及重新给药(含/不含首剂加倍)的效应
Hiroyoshi Matsui,Le Thien Truc Pham,Eyob Adane
Hiroyoshi Matsui
Background: Ticagrelor is an oral P2Y12 receptor antagonist used mostly in combination with aspirin, in patients with acute coronary syndromes (ACS). Ticagrelor is discontinued 3-5 days before major procedures. Due to its...
Population Pharmacokinetic Model Evaluation with a Small Real-World Dataset Versus a Large Virtual Dataset: Does Sample Size Affect Decision-Making? [0.03%]
基于小样本的真实世界数据与大样本的虚拟仿真人羣药动学模型评价：样本量影响决策吗？
Mehdi El Hassani,Daniel J G Thirion,Amélie Marsot
Mehdi El Hassani
Background and objective: In a recent simulation-based study, we found that sample size had minimal influence on the external evaluation of population pharmacokinetic (PK) models. However, the applicability of these findi...
Amarinder Singh,Bernd Meibohm
Amarinder Singh
Assessing the Effect of Food on the Pharmacokinetics of Iclepertin in Healthy Volunteers: A Phase I, Open-Label, Randomised, Cross-over Trial [0.03%]
在健康志愿者中评估食物对艾伯维公司IL-17抑制剂伊克珠单抗药代动力学影响的一项I期、开放性、随机交叉试验
Shilpa Madari,Kerstin Breithaupt-Groegler,Brett A English et al.
Shilpa Madari et al.
Background and objectives: Iclepertin, a selective glycine transporter-1 inhibitor, was investigated as a potential treatment for cognitive impairment associated with schizophrenia. The objective of this trial was to dete...
Association of CYP3A5, ABCB1, and CYP2C8 Polymorphisms with Renal Function in Kidney Transplant Recipients Receiving Tacrolimus [0.03%]
他克莫司接受者的肾移植受者中CYP3A5、ABCB1和CYP2C8多态性与肾功能的关系
Zühal Kaltuş,Nuşin Harmancı,Garip Şahin et al.
Zühal Kaltuş et al.
Background/objectives: Tacrolimus (TAC, FK-506) is a calcineurin inhibitor commonly used to prevent organ rejection in transplant patients. It has a narrow therapeutic index and nephrotoxic effects, characterized by inter...